Antibiotics have long been the go-to treatment for a bacterial stomach bug. The fact that they eliminate harmful bacteria while also disrupting the broader gut microbiome is accepted as a necessary side effect. University of Rhode Island researcher Amanda Alker intends to disprove this by developing targeted microbiome-editing approaches using CRISPR-associated transposons, or CASTs, to
Already a Subscriber? Log in
To Continue Reading This Article
Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.Learn More and Become a Subscriber
- Critical RI business news and analysis updated daily.
- 1 year of print (26 issues).
- Unlimited access to all subscriber only content on our website, on any device.
- Free email alerts.
- Annual Book of Lists Print Edition.
- All special issues produced during subscription term.
Click Here to purchase a paywall bypass link for this article
PBN Branded Content
Beyond Cash Donations: How New Forms of Giving Are Transforming Not-for-Profit Accounting
Evolving Funding Landscape for Not-for-Profits Not-for-profit organizations are being asked to do more with less,…
Learn More
